Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPersonalis Inc

Personalis Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
15.96 USD 0.08 ( 0.50%)
Last update at 2026-11-11T21:00:00Z
VOLUME
1138700
Market Cap
67.00M

Momentum Score

…

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
15.90
Low
16.04
High
52 Week Price Range
0.89
Low
2.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Personalis provides genome-scale sequencing and analytics to support precision oncology and immunotherapy development for biopharma and clinical research customers. Long-term growth may be supported by rising demand for neoantigen discovery, biomarker-driven trials and outsourcing of complex genomic assays; Personalis appears positioned to benefit from its assays and analytics that could generate recurring collaboration and commercial revenue.
Material risks include intense competition from larger diagnostics and sequencing companies, dependence on biopharma partnerships and clinical adoption, regulatory and reimbursement uncertainty, and the potential need for additional financing to fund ongoing operations.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
15.88
Dividend Yield
-
Revenue TTM
74.15M
Revenue Per Share
1.51
Gross Profit TTM
13.35M
Debt / Equity
0.38
ROE
-58.92%
Net Debt
-8.02M
ROCE
-64.95%
Diluted EPS TTM
-1.83

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -113.28M -65.21M -41.22M -25.07M -19.88M
Minority interest - - - - 0.00M
Net income -113.31M -65.23M -41.28M -25.08M -19.89M
Selling general administrative 63.97M 47.70M 33.69M 22.08M 11.27M
Gross profit 13.35M 31.66M 20.11M 22.08M 11.80M
Reconciled depreciation 8.43M 6.01M 5.76M 4.75M 3.07M
Ebit -115.53M -65.35M -42.15M -22.42M -13.51M
Ebitda -113.07M -65.03M -35.46M -22.24M -10.44M
Depreciation and amortization 2.46M 0.33M 6.68M 0.18M 3.07M
Non operating income net other 2.46M 0.33M 0.93M - -
Operating income -115.53M -65.35M -42.15M -22.42M -13.77M
Other operating expenses 180.58M 150.85M 120.79M 87.62M 51.54M
Interest expense 0.20M 0.18M 0.00M 1.13M 1.89M
Tax provision 0.04M 0.01M 0.06M 0.01M 0.01M
Interest income 2.40M 0.37M 0.95M 1.62M 0.29M
Net interest income 2.19M 0.18M 0.95M 0.49M -1.60M
Extraordinary items - - - - 0.00M
Non recurring - - - - 0.00M
Other items - - - - 0.00M
Income tax expense 0.04M 0.01M 0.06M 0.01M 0.01M
Total revenue 65.05M 85.49M 78.65M 65.21M 37.77M
Total operating expenses 128.88M 97.01M 62.26M 44.50M 25.57M
Cost of revenue 51.70M 53.84M 58.53M 43.13M 25.97M
Total other income expense net 2.26M 0.14M 0.92M -2.66M -4.51M
Discontinued operations - - - - 0.00M
Net income from continuing ops -113.31M -65.23M -41.28M -25.08M -19.89M
Net income applicable to common shares -113.31M -65.23M -41.28M -25.08M -19.89M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 225.10M 292.70M 396.53M 244.84M 157.29M
Other current assets 4.36M 6.81M 7.09M 5.44M 3.38M
Total liab 95.66M 74.56M 86.23M 49.90M 50.60M
Total stockholder equity 129.44M 218.14M 310.30M 194.94M 106.69M
Other current liab 19.62M 11.40M 12.58M 8.86M 5.29M
Common stock 0.01M 0.01M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.00M 0.00M 0.00M
Retained earnings -468.71M -360.41M -247.09M -181.87M -140.59M
Other liab - 0.01M 2.12M 0.72M -
Other assets 0.00M 4.59M 4.83M 12.29M 1.76M
Cash 56.98M 89.13M 105.58M 68.53M 55.05M
Total current liabilities 47.23M 33.13M 31.31M 40.64M 49.96M
Current deferred revenue 3.29M 1.26M 3.98M 21.03M 35.98M
Net debt -8.02M -40.48M -52.79M -57.54M -53.69M
Short term debt 9.41M 7.61M 5.53M 2.44M 1.36M
Short long term debt 1.65M 2.22M 1.81M - -
Short long term debt total 48.96M 48.65M 52.80M 10.99M 1.36M
Other stockholder equity 598.36M 579.46M 557.56M 376.79M 89.99M
Property plant equipment - 61.94M 19.65M 11.83M 15.95M
Total current assets 141.93M 199.70M 318.23M 220.72M 139.58M
Net tangible assets - 218.14M 310.30M 194.94M 106.69M
Short term investments 57.20M 78.53M 181.48M 134.76M 73.24M
Net receivables 17.73M 16.64M 18.47M 6.35M 3.30M
Inventory 5.66M 8.59M 5.61M 2.67M 4.61M
Accounts payable 14.92M 12.85M 9.22M 8.30M 7.34M
Accumulated other comprehensive income -0.22M -0.91M -0.17M 0.02M -0.01M
Common stock total equity - 0.01M 0.00M 0.00M 0.00M
Retained earnings total equity - -360.41M -247.09M -181.87M -
Non currrent assets other 6.16M 4.59M 4.83M 2.02M 1.76M
Non current assets total 83.17M 93.00M 78.30M 24.12M 17.71M
Capital lease obligations 46.08M 46.43M 52.80M 10.99M 2.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 102.43M -48.99M -61.90M -73.20M -73.20M
Change to liabilities 1.19M 1.62M 5.00M -5.52M 20.37M
Total cashflows from investing activities 52.54M -60.07M -65.14M -81.58M -7.85M
Net borrowings -1.10M 3.31M 3.31M -5.00M -0.65M
Total cash from financing activities 1.37M 169.70M 121.27M 134.95M -0.59M
Change to operating activities 11.40M -0.55M 1.09M -1.64M -0.37M
Net income -113.31M -65.23M -41.28M -25.08M -19.89M
Change in cash -16.46M 38.85M 13.48M 35.30M -2.87M
Begin period cash flow 107.38M 68.53M 55.05M 19.74M 22.62M
End period cash flow 90.92M 107.38M 68.53M 55.05M 19.74M
Total cash from operating activities -70.23M -70.83M -42.65M -18.07M 5.57M
Issuance of capital stock 0.00M 162.26M 117.50M 144.71M -
Depreciation 8.43M 6.01M 5.76M 4.75M 3.07M
Other cashflows from investing activities - - - -73.20M 0.00M
Dividends paid - - - - 0.00M
Change to inventory -2.98M 0.03M -1.08M -1.17M -2.07M
Change to account receivables 1.82M -12.12M -3.05M 1.07M -2.52M
Sale purchase of stock 2.46M 166.39M 121.27M 145.42M 0.08M
Other cashflows from financing activities 3.66M 9.30M 3.77M 15.24M 0.05M
Change to netincome 19.54M 14.55M 8.30M 9.53M 6.97M
Capital expenditures 49.90M 11.08M 3.25M 8.38M 7.85M
Change receivables 1.82M -12.12M -3.05M - -
Cash flows other operating 12.10M -15.66M -17.38M - -
Cash and cash equivalents changes -16.33M 38.80M 13.47M - -
Change in working capital 10.61M -31.14M -17.23M -7.26M 15.42M
Stock based compensation 19.43M 14.38M 8.24M 4.86M 1.32M
Other non cash items 4.61M 3.12M 1.47M 1.56M 1.18M
Free cash flow -120.13M -81.91M -45.90M -26.45M -2.28M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PSNL
Personalis Inc		 0.08
0.50%		 15.96 - - 0.89 0.50 0.05 0.01
TMO
Thermo Fisher Scientific Inc		 -0.49
0.07%		 717.71 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -0.80
0.34%		 235.31 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 25.84 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.50
1.94%		 25.10 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Personalis Inc

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

6600 Dumbarton Circle, Fremont, CA, United States, 94555

650 752 1300

https://www.personalis.com

223

Name Title Year Born
Mr. John Stephen West Co-Founder, CEO, Pres & Director 1957
Mr. Aaron L. Tachibana Sr. VP & CFO 1961
Dr. Richard Chen M.D., M.S., MS Sr. VP of R&D and Chief Medical Officer 1971
Dr. Russ B. Altman M.D., Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board NA
Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board 1972
Dr. Atul Butte Co-Founder and Member of Clinical & Scientific Advisory Board NA
Dr. Michael Snyder Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board NA
Ms. Carol J. Tillis VP of Fin. & Admin. NA
Mr. Stephen M. Moore J.D. VP, Gen. Counsel & Corp. Sec. 1972
Mr. Michael J Fitzpatrick VP of Worldwide Sales NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…